Unique Challenges in Managing HAART in HIV Positive Patients
Track:
Educational Sessions
Program Code: 246-L02
Date: Tuesday, December 9, 2008
Time: 2:00 PM to 3:00 PM EST
Location:
S230B
MEETING PLANNING ASSOCIATE:
Click the plus sign to see more detailed information about each speaker.
Daniel Cobaugh, PharmD, FAACT, Director of Research and Program Development, ASHP Research and Education Foundation
„« Fellowship training in clinical toxicology at the Pittsburgh Poison Center/Childrenˇ¦s Hospital of Pittsburgh/University of Pittsburgh
„« Toxicology board certification by the American Board of Applied Toxicology
„« Fourteen years of practice experience in poison center and acute-care toxicology settings
„« Over 75 toxicology-related publications including peer-reviewed articles, book chapters, and abstracts including research on the antidotes ethanol, sodium bicarbonate, and hypertonic saline
„« Toxicology consultant to the World Health Organization International Programme on Chemical Safety and the US Department of Health and Human Services Health Resources and Services Administration
„« Abstract Reviewer, North American Congress of Clinical Toxicology
„« Grant Reviewer, U.S. Department of Health and Human Services/Health Services Research Administration, Poison Control Program
„« University faculty member at the University of Pittsburgh Schools of Pharmacy and Medicine (1989-1993), the University of Rochester School of Medicine and Dentistry (1993-2000), The George Washington University School of Medicine (2000-2003)
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Amy Hirsch, PharmD, BCPS, Clinical Pharmacy Specialist Infectious Disease/HIV, The Louis Stokes Cleveland Veterans Affairs Medical Center
Dr. Hirsch received her PharmD at SUNY Buffalo. She completed a PGY-1 residency at The Johns Hopkins Hospital, followed by a PGY-2 Infectious Disease Residency at The Cleveland Clinic. She currently works at the Cleveland VA Medical Center as the Clinical Pharmacy Specialist in Infectious Disease/HIV where she works on the Inpatient ID service, and sees patients in both HIV and Hepatitis C clinic.
Kathleen Melbourne, PharmD, Associate Director, Medical Scientist, Gilead Sciences
Dr. Melbourne is an Associate Director and HIV Medical Scientist (covering Northeast US) at Gilead Sciences. She began her employment with Gilead Sciences in May 2006. She has been on the faculty of the University of Rhode Island College of Pharmacy since 1998, where she is currently a Clinical Associate Professor of Pharmacy. Dr. Melbourne received her BS and PharmD from the University of Rhode Island College of Pharmacy in 1993 and 1995, respectively. She completed an ASHP-accredited Pharmacy Practice Residency at the University of Pittsburgh Medical Center in 1996. In 1997, she completed an Infectious Disease/HIV Pharmacotherapy Fellowship at the Anti-infective Pharmacology Research Unit, affiliated with the University of Rhode Island College of Pharmacy and Brown University Medical School. From 1997-2006, Dr. Melbourne was the Director of the Pharmacy Care Management Program at Coastal Medical, a private medical group consisting of 16 physicians offices located throughout Rhode Island. During her tenure at Coastal Medical, Dr. Melbourne led the implementation of collaborative pharmacy services throughout the primary care network of Coastal Medical, directed a Pharmacy Residency Program, conducted clinical studies measuring the impact of clinical pharmacy services on patient outcomes, precepted PharmD students from the URI College of Pharmacy, and carried on a clinical practice involving both HIV-infected patients and patients with multiple chronic illnesses. Dr. Melbourne's work at Coastal Medical was recognized in 2000 by the American Pharmacists Association Foundation's Quality Center. Currently, her research and clinical focus is on the metabolic and morphologic changes associated with HIV-infection.
Dr. Yeh is an Assistant Professor at the University of Houston, College of Pharmacy. She received her PharmD from the University of California- San Francisco, completed her pharmacy practice residency (PGY1) at UCSF, did a critical care specialty residency (PGY2) at the University of Illinois at Chicago, and completed a fellowship in HIV pharmacology at the University of North Carolina Chapel Hill. Dr. Yeh’s research interests include: antiretroviral drug interactions, pharmacogenetic associations of drug metabolizing enzymes and drug transporters and their impact on antiretroviral PK/PD, and use of and issues concerning alternative medications in HIV.
Describe which alternative and complementary medicines impact HAART serum concentrations.
Discuss age-related differences in HAART-related adverse drug reactions.
Discuss practical measures to reduce the impact of alternative and complementary medicines on HAART serum concentrations.